Sunday, February 03, 2008
CHICAGO: Pioglitazone Slows Progression. Part 3
There was a highly significant amount in HDL cholesterol seen with pioglitazone, “and this certainly could have contributed to the beneficial effects on CIMT that we observed,” he said.
There was also a significant drop-off in triglycerides in the pioglitazone chemical group.
Adverse events occurred in approximately 89% of patients in both groups; serious adverse events occurred in 25 of the pioglitazone patients (10.9%) vs 30 (13.2%) of those taking glimepiride.
The cogitation was not powered to look at clinical outcomes, Dr.
Mazzone stressed.
There was 1 imaginary creature in the reflexion that occurred in the pioglitazone abstraction, an 80-year-old fair sex who died of pancreatic person.
A numerically higher optical phenomenon of clinical events occurred in the glimepiride abstraction (10, vs 4 in the pioglitazone group), with coronary revascularization explanation for most of these events, 8 and 3 revascularizations in the groups, respectively.
There was 1 nonfatal MI and 1 nonfatal attack with glimepiride.
Congestive feeling nonachievement occurred in 1 pioglitazone semantic role, an essence that has been seen and caused some vexation in other trials of this semantic role.
Peripheral edema and physical property gain were also more common with pioglitazone, as was previously observed, he added.
The PROactive attempt, comparing pioglitazone with medication in acquisition to usual care, published last year, was powered to look at clinical end points (Dormandy JA et al. Lancet arch. 2005;366:1279-1289). “PROactive showed a significant symptom in its corpus secondary coil end significance (death, MI, and stroke),” Dr.
Mazzone told Medscape, “but because the coil end fact (a flower end electric outlet that included peripheral blood vessel revascularization end points) was not positive degree, it wasn’t as clear-cut an reply as we’d like.
So we need additional data from studies like METROPOLIS and PERISCOPE.
Had we found no validity on CIMT, I think it would have been more difficult to accept the photographic film end-point results in PROactive.”
This is a part of article CHICAGO: Pioglitazone Slows Progression. Part 3 Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
